Nottingham University Hospital

The trials here

What the 17 trials at this site are about, from their registry records.

Conditions

• Metastatic breast cancer3 trials
• Colorectal cancer2 trials
• Liver cirrhosis2 trials
• Stroke2 trials
• Triple-negative breast cancer2 trials
• Ankylosing spondylitis1 trial
• Coronary artery disease1 trial
• Crohn's disease1 trial
• Fatty liver disease (MASLD/MASH)1 trial
• Gastric and oesophageal cancer1 trial
• Kidney cancer1 trial
• Liver and biliary tract cancer1 trial
• and 4 more

Phase

• Phase 35 trials
• Phase 23 trials
• Phase 1/22 trials
• Phase 11 trial
• Phase 2/31 trial

Status

• Active, not recruiting6 trials
• Recruiting6 trials
• Completed4 trials
• Not yet recruiting1 trial

Lead sponsor

• Pfizer2 trials
• Resolution Therapeutics Limited2 trials
• Royal Marsden NHS Foundation Trust2 trials
• Boehringer Ingelheim1 trial
• DiaMedica Therapeutics Inc1 trial
• and 9 more

Running trials

• Active, not recruiting

  RTX001 Autologous Engineered Macrophages for Liver Cirrhosis

  NCT06823713· Phase 1/2· Resolution Therapeutics Limited· Source

• Recruiting

  Personalized Medicine for Advanced Biliary Cancer Patients

  NCT05615818· Phase 3· UNICANCER· Source

  Contact: Aurora ARVIND, MD

• Recruiting

  Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

  NCT06324357· Phase 1/2· Boehringer Ingelheim· Source

  Contact: Boehringer Ingelheim

• Active, not recruiting

  Study in Patients With Decompensated Liver Cirrhosis

  NCT06380335· Resolution Therapeutics Limited· Source

• Recruiting

  Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD)

  NCT04939935· Phase 3· The University of Queensland· Source

  Contact: Matthew Hall, Dr

• Recruiting

  Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II

  NCT05102019· Shockwave Medical, Inc.· Source

  Contact: Jane Quinn

• Recruiting

  Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)

  NCT05065216· Phase 2/3· DiaMedica Therapeutics Inc· Source

  Contact: Jo Wright

• Active, not recruiting

  Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)

  NCT04822181· Phase 3· Novo Nordisk A/S· Source

• Active, not recruiting

  PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer

  NCT04360941· Phase 1· Royal Marsden NHS Foundation Trust· Source

• Active, not recruiting

  Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer

  NCT04114825· Phase 2· RhoVac APS· Source

• Recruiting

  Renal Adjuvant MultiPle Arm Randomised Trial

  NCT03288532· Phase 3· University College, London· Source

  Contact: Poulam Patel (principal investigator)

• Recruiting

  Tracking Mutations in Cell Free Tumour DNA to Predict Relapse in Early Colorectal Cancer

  NCT04050345· Royal Marsden NHS Foundation Trust· Source

  Contact: Hsiang-Chi Chen, MSc

• Recruiting

  Exactech Shoulder Post Market Clinical Follow-up Study

  NCT05603728· Exactech· Source

  Contact: Donna King

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Ankylosing spondylitis1 recruiting
• Colorectal cancer1 recruiting
• Coronary artery disease1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Kidney cancer1 recruiting
• Liver and biliary tract cancer1 recruiting
• Metastatic breast cancer1 recruiting
• Osteoarthritis1 recruiting
• Polycystic kidney disease1 recruiting
• Rheumatoid arthritis1 recruiting
• Stroke1 recruiting

Closed trials

• Completed

  A Study of Surgical Interventions in Fistulizing Conditions

  NCT04940611· Takeda· Source

• Completed

  A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion

  NCT02398656· Phase 3· University of Calgary· Source

• Completed

  Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer

  NCT02007512· Phase 2· Pfizer· Source

• Completed

  Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer

  NCT01889238· Phase 2· Pfizer· Source